Aubrey Rankin - Director, Revance Therapeutics, Inc

As of March 17, 2022


Aubrey Rankin Net Worth

  • Net worth is estimated to be at least $17.24M
  • Owns at least 417,074 units of Revance Therapeutics, Inc stock
  • Sold an estimated value of $8.82M in the last 2 years at Revance Therapeutics, Inc

Aubrey Rankin Trading

  • Largest purchase of shares was 30,000 units , worth over $432.88K on December 6, 2021
  • Largest sale of shares was 55,382 units , worth over $1.65M on July 28, 2021
  • In total has made about 14 transactions over 2 years
  • Usually trades in July, with the busiest year in 2021
Ticker
Type
Value
Price per Share
Shares
Filing Date
No matching records found
1

Aubrey Rankin Mailing Address

  • Mailing address is C/o Revance Therapeutics, Inc 7555 Gateway Blvd Newark CA 94560 CA

Revance Therapeutics, Inc Executive Compensation

Name
Year
Salary
Bonus
Stock Awards
Option Awards
Other Earnings Plans or Compensations
Other Compensation
Total
Mark J. Foley 2020 $650,000 $ $7,794,350 $ $328,331 $8,255 $8,780,936
Mark J. Foley 2019 $189,764 $150,000 $11,728,370 $5,112,573 $ $9,723 $17,190,430
Tobin C. Schilke 2020 $421,375 $ $1,131,345 $1,273,662 $143,186 $11,531 $2,981,099
Tobin C. Schilke 2019 $407,126 $25,000 $86,150 $299,781 $178,123 $11,078 $1,007,258
Tobin C. Schilke 2018 $64,644 $25,000 $449,280 $1,434,350 $ $233 $1,973,507
Abhay Joshi, Ph.D. 2020 $514,608 $ $1,405,850 $1,913,759 $213,726 $11,731 $4,059,674
Abhay Joshi, Ph.D. 2019 $485,479 $ $271,373 $939,314 $204,211 $9,520 $1,909,897
Abhay Joshi, Ph.D. 2018 $469,062 $ $342,513 $1,192,465 $232,186 $9,210 $2,245,436
Dustin Sjuts 2020 $415,000 $ $1,294,250 $1,306,320 $141,020 $66,242 $3,222,832
Dustin Sjuts 2019 $378,333 $50,000 $43,075 $99,927 $183,902 $45,786 $801,023
Dwight Moxie 2020 $370,104 $125,000 $1,309,383 $2,579,240 $125,426 $10,356 $4,519,508
No matching records found

Source: https://www.sec.gov/Archives/edgar/data/1479290/000147929021000089/rvncfy20proxystatementdef1.htm

Revance Therapeutics, Inc Insider Trading

  • The most recent transaction was 6,400 units bought on December 15, 2021 by Angus Russell worth over $100.74K
  • In the last 7 years, insiders at Revance Therapeutics, Inc sold an estimated value of $29.8M and bought an estimated value of $8.6M
  • The most active traders are Daniel Browne, CEO and President,  Curtis Ruegg, EVP,  and Lauren Silvernail, CFO & CBO
  • Insider trading is most common in May, with the busiest year in 2021

Revance Therapeutics, Inc. Insider Trades

Insider Names
Type
Value
Price per Share
Shares
Filing Date
No matching records found
1